Nigel Paneth

Nigel Paneth

Auto-generated profile, based on publicly available information

Nigel Paneth

Michigan State University

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2005 in Developmental Medicine & Child Neurology
Verified
Journal Article
Closed access
PDF file
MBMartin Bax
Martin Bax
MGMurray Goldstein
Murray Goldstein
PRPeter and Suzanne Rosenbaum
Peter and Suzanne Rosenbaum
ALAlan Leviton
Alan Leviton
NPNigel Paneth
Nigel Paneth
DDDiane Damiano
Diane Damiano
Because of the availability of new knowledge about the neurobiology of developmental brain injury, information that epidemiology and modern brain imaging is providing, the availability of more precise measuring instruments of patient performance, and the increase in studies evaluating the efficacy of therapy for the consequences of injury, the need for reconsideration of the definition and classification of cerebral palsy (CP) has become evident. Pertinent material was reviewed at an international symposium participated in by selected leaders in the preclinical and clinical sciences. Suggestions were made about the content of a revised definition and classification of CP that would meet the needs of clinicians, investigators, and health officials, and provide a common language for improved communication. With leadership and direction from an Executive Committee, panels utilized this information and have generated a revised Definition and Classification of Cerebral Palsy. The Executive Committee presents this revision and welcomes substantive comments about it.

1 February 2007
Verified
Journal Article
Closed access
PRPeter Rosenbaum
Peter Rosenbaum
NPNigel Paneth
Nigel Paneth
ALAlan Leviton
Alan Leviton
MGMurray Goldstein
Murray Goldstein
MBMartin Bax
Martin Bax
BJBo Jacobsson
Bo Jacobsson

1 June 2020 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
EBEvan M. Bloch
Evan M. Bloch
SSShmuel Shoham
Shmuel Shoham
ACArturo Casadevall
Arturo Casadevall
BSBruce S. Sachais
Bruce S. Sachais
BSBeth Shaz
Beth Shaz
ATAaron A.R. Tobian
Aaron A.R. Tobian
Severe acute respiratory syndrome coronavirus 2 (SARS–CoV-2), the cause of coronavirus disease 2019 (COVID-19), has spurred a global health crisis. To date, there are no proven options for prophylaxis for those who have been exposed to SARS–CoV-2, nor therapy for those who develop COVID-19. Immune (i.e., “convalescent”) plasma refers to plasma that is collected from individuals following resolution of infection and development of antibodies. Passive antibody administration through transfusion of convalescent plasma may offer the only short-term strategy for conferring immediate immunity to susceptible individuals. There are numerous examples in which convalescent plasma has been used successfully as postexposure prophylaxis and/or treatment of infectious diseases, including other outbreaks of coronaviruses (e.g., SARS-1, Middle East respiratory syndrome [MERS]). Convalescent plasma has also been used in the COVID-19 pandemic; limited data from China suggest clinical benefit, including radiological resolution, reduction in viral loads, and improved survival. Globally, blood centers have robust infrastructure for undertaking collections and constructing inventories of convalescent plasma to meet the growing demand. Nonetheless, there are nuanced challenges, both regulatory and logistical, spanning donor eligibility, donor recruitment, collections, and transfusion itself. Data from rigorously controlled clinical trials of convalescent plasma are also few, underscoring the need to evaluate its use objectively for a range of indications (e.g., prevention vs. treatment) and patient populations (e.g., age, comorbid disease). We provide an overview of convalescent plasma, including evidence of benefit, regulatory considerations, logistical work flow, and proposed clinical trials, as scale-up is brought underway to mobilize this critical resource.

1 September 2020 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
MJMichael Joyner
Michael Joyner
KBKatelyn Ann Bruno
Katelyn Ann Bruno
SKStephen A. Klassen
Stephen A. Klassen
KKKatie L Kunze
Katie L Kunze
PJPatrick Johnson
Patrick Johnson
RWR. Scott Wright
R. Scott Wright

6 October 2010 in BMJ
Verified
Journal Article
Closed access
NPNigel Paneth
Nigel Paneth
Low scores are strongly associated with cerebral palsy and its subtypes The first large study of Apgar score at birth and the risk of cerebral palsy was the US National Collaborative Perinatal Project. It found that most cases of cerebral palsy occurred in children with normal Apgar scores; that the risk of cerebral palsy was strongly related to an Apgar score lower than 4 in normal weight infants, especially when the low score was prolonged; and that low Apgar scores were less predictive of cerebral palsy in low birthweight infants⇓.1 Library of Congress/Science Photo Library In the linked study (doi:10.1136/bmj.c4990), Lie and colleagues confirm—in a Norwegian dataset 10 times larger (540 000 children)—all of these findings but add the new observation that the risk of cerebral palsy by Apgar score depends on the type of cerebral palsy. Hemiplegia was 10 times more common in babies with Apgar score less than 4, diplegia 22 times more common, but quadriplegia 137 times more common.2 Although the nature of the insult or insults in cerebral palsy is still unclear, …

27 July 2020 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MJMichael Joyner
Michael Joyner
RWR. Scott Wright
R. Scott Wright
DFDeLisa Fairweather
DeLisa Fairweather
JSJonathon W. Senefeld
Jonathon W. Senefeld
KBKatelyn Ann Bruno
Katelyn Ann Bruno
ACArturo Casadevall
Arturo Casadevall
BACKGROUND. Convalescent plasma is the only antibody-based therapy currently available for patients with coronavirus disease 2019 (COVID-19). It has robust historical precedence and sound biological plausibility. Although promising, convalescent plasma has not yet been shown to be safe as a treatment for COVID-19. METHODS. Thus, we analyzed key safety metrics after transfusion of ABO-compatible human COVID-19 convalescent plasma in 5000 hospitalized adults with severe or life-threatening COVID-19, with 66% in the intensive care unit, as part of the US FDA expanded access program for COVID-19 convalescent plasma. RESULTS. The incidence of all serious adverse events (SAEs), including mortality rate (0.3%), in the first 4 hours after transfusion was <1%. Of the 36 reported SAEs, there were 25 reported incidences of related SAEs, including mortality (n = 4), transfusion-associated circulatory overload (n = 7), transfusion-related acute lung injury (n = 11), and severe allergic transfusion reactions (n = 3). However, only 2 of 36 SAEs were judged as definitely related to the convalescent plasma transfusion by the treating physician. The 7-day mortality rate was 14.9%. CONCLUSION. Given the deadly nature of COVID-19 and the large population of critically ill patients included in these analyses, the mortality rate does not appear excessive. These early indicators suggest that transfusion of convalescent plasma is safe in hospitalized patients with COVID-19. TRIAL REGISTRATION. ClinicalTrials.gov NCT04338360. FUNDING. Mayo Clinic, Biomedical Advanced Research and Development Authority (75A50120C00096), National Center for Advancing Translational Sciences (UL1TR002377), National Heart, Lung, and Blood Institute (5R35HL139854 and R01 HL059842), National Institute of Diabetes and Digestive and Kidney Diseases (5T32DK07352), Natural Sciences and Engineering Research Council of Canada (PDF-532926-2019), National Institute of Allergy and Infectious Disease (R21 AI145356, R21 AI152318, and AI152078), Schwab Charitable Fund, United Health Group, National Basketball Association, Millennium Pharmaceuticals, and Octapharma USA Inc.